Claims
- 1. A method for screening and selecting a candidate substance for sufficient binding and/or that inhibits binding to a CEACAM1 or a structurally related CEA family member molecule comprising:
preparing a soluble CEACAM1antigen comprising a functional binding domain, D1, having a protruding, convoluted CC′ loop amino acid sequence of K G E R V D G N R Q a C-terminal domain, D4, having an elongated CD loop, and a flexible linker connecting D1 to D4, to provide a target molecule; preparing a control sample comprising the target molecule and a monoclonal antibody or other antibody-like functionally equivalent molecules having specific binding affinity for the CC′ loop or that competes for binding to serial CC′ loop, and preparing a test sample comprising the target molecule and a candidate substance; incubating the control sample and the test sample for a period of time and under appropriate conditions to permit binding to the target molecule in the control sample; and comparing the amount of bound target molecule in the control sample to the amount of candidate agent bound to the target molecule in the test sample, wherein a candidate agent having at least 40% the amount of bound candidate agent to target molecule compared to the amount of bound target molecule in the control sample is selected as having sufficient binding/inhibiting activity.
- 2. The method of claim 1 wherein D1 of the CEACAM1 antigen farther comprises a first and a second anti-parallel beta-sheet connected to one another by a salt bridge.
- 3. The method of claim 1 wherein the biological activity inhibited is cell adhesion, tumor metastasis, angiogenesis, virus binding and/or infection, or bacterial or infection and/or infection.
- 4. The method of claim 1 wherein the candidtaet molecule binds or inhibits binding to a ligand comprising homophilic binding domain of CEACAM1, MHV viral spike glycoprotein, Neisseria, or Hemophilus bacteria.
- 5. The method of claim 1 wherein the target molecule comprises a cell surface receptor.
- 6. The method of claim 5 wherein the target molecule comprises a cell surface protein on an epithelial cell, a leukocyte, an endothelial cell, or a placental cell.
- 7. The method of claim 1 wherein the selected candidate substance inhibits virus binding.
- 8. The method of claim 4 wherein the selected candidate substance inhibits binding of a pathogenic strain of bacteria of Neisseria or Hemophilus.
- 9. The method of claim 8 wherein the pathogenic strain is a Hemophilus strain.
- 10. The method of claim 1 wherein the selected candidate substance is capable of blocking cell-mediated immune responses.
- 11. The method of claim 1 wherein the selected candidate substance provides a bacterial inhibiting activity.
- 12. The method of claim 11 wherein the selected candidate substance provides a treatment for bacterial infection.
- 13. The method of claim 10 wherein the selected candidate substance provides a treatment for diarrhea.
- 14. The method of claim 10 wherein the selected candidate substance provides a treatment for hepatitis.
- 15. A soluble peptide in the CEA family comprising:
a hydrophobic core structure; a functional binding domain D1 having a convoluted and protruding CC′ loop structure; and a carboxy terminal D4 containing an elongated CD loop.
- 16. The soluble CEA family peptide of claim 15 further defined as having an A-A′ kink comprising a cis-proline amino acid residue.
- 17. The soluble CEA family peptide of claim 15 further comprising a detectable molecular tag molecule.
- 18. The soluble CEA family peptide of claim 15 further defined as comprising an amino acid sequence of SEQ ID NO: 1.
- 19. The soluble CEA family protein of claim 15 further defined as comprising an amino acid sequence of SEQ ID NO: 2.
- 20. The soluble CEA family protein of claim 15 further defined as comprising an amino acid sequence of SEQ ID NO: 3.
- 21. The soluble CEA family protein of claim 15 further defined as a cellular receptor for a coronavirus.
- 22. A pharmaceutical formulation comprising the peptide of claim 14 in a pharmaceutically acceptable excipient.
- 23. The pharmaceutical formulation of claim 22 further defined as an antiviral agent.
- 24. An antiviral agent comprising a molecule capable of binding with high affinity and under stringent conditions to a target antigen molecule having:
a virus binding domain, D1, having a protruding, convoluted CC′ loop, and an A-A′ kink; a C-terminal domain, D4, having an elongated CD loop, and a flexible linker connecting D1 to D4.
- 25. The antiviral agent of claim 24 wherein the anti-viral agent is further defined as binding to the target antigen molecule with an affinity of about 104 to about 1010.
- 26. A method for selecting a pharmaceutical candidate compound comprising;
a) immobilizing a CEACAM1 molecule having a sequence of SEQ ID NO. 1 or SEQ ID NO. 2 to a surface of a microtitor well having a plurality of wells; b) adding an aliquot of a molecular library containing a number of library members; c) adding cells having a detectable label that express a ligand for CEACAM1 to the wells; d) incubating the well comoponents for a period sufficient to permit cells to bind immobilized CEACAM1; and e) washing the wells to remove non-adherant cells; wherein bound labeled cells identify the library members that are selected as a pharmaceutical candidate.
- 27. The method of claim 26 wherein the cells are labeled with Cr51 or a flourescent dye.
RELATED APPLICATIONS
[0001] This present invention claims priority to U.S. application Ser. No. 10/118,471 filed Apr. 5, 2002.
GOVERNMENT LICENSE RIGHTS
[0002] The United States Government may own rights to the invention as research relevant to its development was funded by NIH Grants AI26075, GM56008, HL48675, and AI25231.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10118471 |
Apr 2002 |
US |
Child |
10138176 |
May 2002 |
US |